Hedy Kindler to Pemetrexed
This is a "connection" page, showing publications Hedy Kindler has written about Pemetrexed.
Connection Strength
1.373
-
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021 11; 27(11):1910-1920.
Score: 0.197
-
Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. Clin Lung Cancer. 2020 11; 21(6):553-561.e1.
Score: 0.179
-
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. Invest New Drugs. 2020 04; 38(2):457-467.
Score: 0.165
-
Peritoneal mesothelioma: the site of origin matters. Am Soc Clin Oncol Educ Book. 2013; 182-8.
Score: 0.107
-
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012 Sep; 77(3):567-71.
Score: 0.103
-
Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol. 2008 Jun; 9(2-3):171-9.
Score: 0.079
-
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005 Oct; 16(10):1639-45.
Score: 0.064
-
The emerging role of pemetrexed for the treatment of malignant mesothelioma. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):49-53.
Score: 0.059
-
Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec; 29(6 Suppl 18):49-53.
Score: 0.053
-
The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer. 2002 Aug 15; 95(4 Suppl):928-32.
Score: 0.052
-
Pemetrexed in patients with gastrointestinal carcinoma. Semin Oncol. 2002 Apr; 29(2 Suppl 5):42-9.
Score: 0.051
-
Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer. 2021 02; 124(3):564-566.
Score: 0.046
-
Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2019 10 01; 25(19):5787-5798.
Score: 0.042
-
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 01; 20(23):5927-36.
Score: 0.030
-
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer. 2014 Sep; 85(3):429-34.
Score: 0.030
-
Disease volumes as a marker for patient response in malignant pleural mesothelioma. Ann Oncol. 2013 Apr; 24(4):999-1005.
Score: 0.026
-
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009 Jun 20; 27(18):3007-13.
Score: 0.021
-
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008 Jul 20; 26(21):3567-72.
Score: 0.020
-
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol. 2008 Mar 20; 26(9):1465-71.
Score: 0.019
-
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):549-58.
Score: 0.018
-
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003 Apr 15; 21(8):1556-61.
Score: 0.014